Finance

Lists
WST:NYSE
West Pharmaceutical Services Inc
US$397,34
+1,24%
(+4,86) 1D
6 ພ.ຈ., 15 ໂມງ 50 ນາທີ 08 ວິນາທີ GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for WST...
Open
US$389,62
High
US$402,40
Low
US$386,88
Mkt. cap
27,68 ຕື້
Avg. vol.
677,21 ພັນ
Volume
273,36 ພັນ
Dividend
0,26%
Quarterly dividend
US$0,26
Ex-dividend date
29 ກ.ລ. 2026
P/E ratio
44,56
52-wk high
US$438,27
52-wk low
US$223,83
EPS
US$8,92
Beta
1,13
Shares outstanding
69,66 ລ້ານ
No. of employees
11 ພັນ
Open
US$389,62
High
US$402,40
Low
US$386,88
Mkt. cap
27,68 ຕື້
Avg. vol.
677,21 ພັນ
Volume
273,36 ພັນ
Dividend
0,26%
Quarterly dividend
US$0,26
Ex-dividend date
29 ກ.ລ. 2026
P/E ratio
44,56
52-wk high
US$438,27
52-wk low
US$223,83
EPS
US$8,92
Beta
1,13
Shares outstanding
69,66 ລ້ານ
No. of employees
11 ພັນ
News stories
From web sources and news partners
Zacks
Zacks
·
3 ຊົ່ວໂມງກ່ອນ
10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
MyChesCo
MyChesCo
·
4 ຊົ່ວໂມງກ່ອນ
West Pharmaceutical Raises Outlook as Earnings Surge 57%
Profile
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin. Wikipedia
About West Pharmaceutical Services Inc
CEOEric M. Green
Employees10,8 ພັນ
Founded1923
HeadquartersWest Whiteland Township, ເພນຊີນວາເນຍ, ສະຫະລັດ
SectorHealth Care
Industry-
Analyst ratings
Based on 6 analysts giving stock ratings to WST in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for WST in the last 3 months.
Highest
Current US$397,34
US$500,00 (+25,84%)
Average
US$478,17 (+20,34%)
Lowest
US$400,00 (+0,67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brendan Smith
TD Cowen
Buy
Maintained
US$500,00
+25,8%
10/29/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
US$480,00
+20,8%
10/30/2026
Unknown Analyst
UBS
Buy
Maintained
US$495,00
+24,6%
10/30/2026
Doug Schenkel
UBS
Buy
Maintained
US$495,00
+24,6%
10/30/2026
Joanne Wuensch
Citi
Buy
Reiterated
US$494,00
+24,3%
10/30/2026
Luke Sergott
Barclays
Buy
Maintained
US$500,00
+25,8%
10/30/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Upgraded
US$400,00
+0,7%
09/22/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
US$410,00
+3,2%
07/24/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/23/2026
Curtis Moiles
Exane BNP Paribas
Buy
Initiated
US$447,00
+12,5%
07/13/2026
Paul Knight
KeyBanc
Buy
Maintained
US$390,00
-1,8%
07/02/2026
Michael Polark
Wolfe Research
Buy
Reiterated
US$375,00
-5,6%
06/01/2026
Patrick B Donnelly
Citi
Buy
Maintained
US$400,00
+0,7%
04/24/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
-
-
04/23/2026
Dan Leonard
UBS
Buy
Maintained
US$340,00
-14,4%
02/13/2026
Justin Bowers
Deutsche Bank
Buy
Maintained
US$315,00
-20,7%
02/13/2026
David Windley
Jefferies
Buy
Maintained
US$295,00
-25,8%
02/10/2026
Nico Chen
DBS
Buy
Maintained
US$320,00
-19,5%
01/28/2026
Last report
29 ຕ.ລ. 2026
Fiscal period
Q3 2026
US$2,66 / US$2,20
+21,12%beat
Revenue / Est. (USD)
874,50 ລ້ານ / 826,55 ລ້ານ
+5,80%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
ກ.ຍ. 2026
Revenue
805,00 ລ້ານ
844,90 ລ້ານ
872,30 ລ້ານ
874,50 ລ້ານ
Cost of goods sold
501,10 ລ້ານ
548,50 ລ້ານ
543,10 ລ້ານ
527,10 ລ້ານ
Cost of revenue
501,10 ລ້ານ
548,50 ລ້ານ
543,10 ລ້ານ
527,10 ລ້ານ
Research and development expenses
21,80 ລ້ານ
15,80 ລ້ານ
19,70 ລ້ານ
18,30 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
107,50 ລ້ານ
99,50 ລ້ານ
112,00 ລ້ານ
108,80 ລ້ານ
Operating expense
129,70 ລ້ານ
113,10 ລ້ານ
133,20 ລ້ານ
125,50 ລ້ານ
Total operating expenses
630,80 ລ້ານ
661,60 ລ້ານ
676,30 ລ້ານ
652,60 ລ້ານ
Operating income
174,20 ລ້ານ
183,30 ລ້ານ
196,00 ລ້ານ
221,90 ລ້ານ
Other non operating income
600,00 ພັນ
-200,00 ພັນ
-200,00 ພັນ
-200,00 ພັນ
EBT including unusual items
165,40 ລ້ານ
183,50 ລ້ານ
186,20 ລ້ານ
272,00 ລ້ານ
EBT excluding unusual items
181,20 ລ້ານ
188,60 ລ້ານ
201,20 ລ້ານ
225,60 ລ້ານ
Income tax expense
33,30 ລ້ານ
44,70 ລ້ານ
32,20 ລ້ານ
58,00 ລ້ານ
Effective tax rate
20,13%
24,36%
17,29%
21,32%
Other operating expenses
400,00 ພັນ
-2,20 ລ້ານ
1,50 ລ້ານ
-1,60 ລ້ານ
Net income
132,10 ລ້ານ
138,80 ລ້ານ
154,00 ລ້ານ
214,00 ລ້ານ
Net profit margin
16,41%
16,43%
17,65%
24,47%
Earnings per share
2,04
2,13
2,37
2,66
Interest and investment income
5,30 ລ້ານ
5,10 ລ້ານ
3,80 ລ້ານ
4,30 ລ້ານ
Interest expense
-
-1,90 ລ້ານ
-2,60 ລ້ານ
-3,80 ລ້ານ
Net interest expenses
5,30 ລ້ານ
3,20 ລ້ານ
1,20 ລ້ານ
500,00 ພັນ
Depreciation and amortization charges
-
-
-
-
EBITDA
221,20 ລ້ານ
228,50 ລ້ານ
242,20 ລ້ານ
267,80 ລ້ານ
Gain or loss from assets sale
-
-
-
-55,70 ລ້ານ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
ແອັບຂອງ Google